Repligen Corp Dossier - Source-backed chat

Repligen Corp

RGENNASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)1.05

Intrinsic Value $46.52median of 3 methodsbased on filings through 31 Dec 2025

Market Price $177.23Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 74% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-74%)

Data confidence Sign in to view data confidence

Market Cap $10B

Enterprise Value $10B

Shares Outstanding 56.4M diluted

Next Earnings Date27 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Repligen is positioned as a premier pure-play supplier in the bioprocessing market, benefiting from a cyclical recovery in life sciences tools and robust demand for advanced modalities. Following a challenging period of inventory destocking in 2024, the company's Q1 2026 results demonstrate a strong operational rebound, highlighted by 11% organic revenue growth and exceptional performance in its Process Analytics and Chromatography franchises. With a solid balance sheet, a newly established Transformation Office focused on margin expansion, and strategic regionalization efforts (such as its OEM partnership in China), Repligen is well-equipped to outpace industry growth and expand its EBITDA margins toward its long-term target of ~30% by 2030.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets20 analysts · as of 18 Aug 2026

Low · most bearish analyst$145.00

Mean target$185.70

High · most bullish analyst$220.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$145.00

Prolonged funding constraints for small-to-mid-sized biotech companies and slower adoption of gene therapy platforms. Customer inventory management persists longer than anticipated, leading to volatile order patterns. Operational execution delays in the China OEM partnership or failure to realize cost savings from the Transformation Office limit margin expansion.

Base CaseCentral scenario

$185.70

Matches the consensus mean

Steady recovery in bioprocessing demand with organic revenue growth tracking within the guided 9%-13% range for FY26. Consumables demand remains stable, and Chromatography/Analytics franchises grow at double-digit rates. Operating margins expand gradually as volume leverage and product mix offset tariff and localized pricing pressures, keeping the company on track for its multi-year growth targets.

Bull CaseUpside scenario

$220.00

Accelerated bioprocessing market recovery driven by rapid adoption of new modalities (cell and gene therapies, mRNA) and a faster-than-expected rebound in emerging biotech funding. Process Analytics continues to grow at >50% as customers transition to 'Bioprocessing 4.0' real-time monitoring. The China OEM partnership drives market share gains, and the Transformation Office achieves margin targets ahead of schedule.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pure-play exposure to high-growth bioprocessing consumables and systems with high switching costs.
Strong secular tailwinds from the commercialization of biologics, biosimilars, and cell/gene therapies.
Market leadership in Process Analytics (SoloVPE, FlowVPX) enabling real-time monitoring and Bioprocessing 4.0 transition.
Robust balance sheet with $785 million in cash and marketable securities to support strategic M&A.

Key Investment Risks

High valuation multiples relative to historical averages and larger diversified peers.
Exposure to cyclical biotech funding environments and customer concentration risks.
Geopolitical and tariff headwinds, particularly in the Chinese market.
Integration risks associated with an active M&A strategy.

Thesis Invalidation Triggers

Organic revenue growth falling below the guided range of 9%-13% for the full year 2026.
Adjusted operating margins contracting below the guided range of 15.1%-15.5% for the full year 2026.
Significant loss of market share in key franchises like Filtration or Analytics to larger competitors like Cytiva (Danaher) or Sartorius.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.